LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Precigen Inc.
Headquarters:
Germantown, MD, United States
Website:
https://precigen.com/
Year Founded:
1998
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Helen Sabzevari, PhD
Number Of Employees:
143
Enterprise Value:
$235,664,717
PE Ratio:
-2.76
Exchange/Ticker 1:
NASDAQ:PGEN
Exchange/Ticker 2:
N/A
Latest Market Cap:
$392,569,504
BioCentury
|
Jan 23, 2025
Management Tracks
New COOs for Vividion, Edgewise
Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx
Read More
BioCentury
|
Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
Read More
BioCentury
|
Aug 9, 2024
Finance
Public equity report: Symbiotic Capital launches with $600M credit fund
Plus: TG Therapeutics’ $250M term loan, and public raises by Tenax, MindMed
Read More
BioCentury
|
Feb 16, 2024
Product Development
Creating CAR T therapies that don’t cause cancer
Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem
Read More
BioCentury
|
Jan 26, 2023
Finance
Jan. 25 Finance Quick Takes: Pliant leads follow-on pack
Plus: Dimension launches with $350M fund for start-ups, and updates from Atomic AI
Read More
BioCentury
|
Jan 21, 2023
Product Development
Rapid CAR T manufacturing is about more than speed
Autologous CAR T developers cite safety, efficacy and access benefits from rapid manufacturing platforms
Read More
BioCentury
|
Sep 21, 2022
Management Tracks
Sharma and Lippman join Alnylam C-suite
Plus Shah now COO at Precigen and updates from Carmot, Evozyne, Matinas, Maxwell and more
Read More
BioCentury
|
Mar 25, 2022
Discovery & Translation
AACR22 tackles the CAR T solid tumor challenge
Dual-targeting CARs, new targets and bispecific adaptors among the top innovations
Read More
BioCentury
|
Mar 11, 2022
Management Tracks
Sandrock joins board at Atalanta
Plus Imbria staffs C-suite and updates from Berkeley Lights, Akouos and more
Read More
BioCentury
|
Jan 8, 2022
Management Tracks
Totus recruits Singer as first CFO
Plus updates from Pharmaron, Adverum, Azenta, InterVenn and more
Read More
Items per page:
10
1 - 10 of 38